Randomized Embolization Trial for NeuroEndocrine Tumour Metastases To The Liver

Official Title

Randomized Embolization Trial for NeuroEndocrine Tumour Metastases To The Liver

Summary:

The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.

Trial Description

Primary Outcome:

• Abdominal MRI/Triple Phase CT

• Number of Adverse Events

View this trial on ClinicalTrials.gov